Medline Inc. (MDLN) Raises 2026 Organic Sales Outlook to 10.0%-10.5%

What happened

Medline raised its 2026 organic sales growth outlook to 10.0%-10.5%, from 9.0%-10.0%, and reaffirmed Adjusted EBITDA guidance of $3.3B-$3.4B. Third-quarter sales rose 10.4% to $7.9B year over year, while net income fell 1.2% to $318M.

Confirmed

Global impact / market context

The higher sales outlook indicates Medline expects stronger growth, but the quarter shows that more revenue did not produce higher net income. Inflation-related inventory costs, higher expenses and customer mix weighed on profit, while adjusted earnings also included tariff-refund benefits.

Analyst inference

Medline’s results present a mixed operating picture: sales and Adjusted EBITDA increased, but net income declined. The reaffirmed 2026 Adjusted EBITDA range excludes tariff refunds, so investors can distinguish the company’s stated earnings outlook from those refund benefits.

Analyst inference

What to watch

1. Check upcoming results for whether organic sales growth supports net income growth, rather than being offset by inflation-related inventory costs, higher expenses or customer mix. Analyst inference
2. Compare reported Adjusted EBITDA with the $3.3B-$3.4B 2026 guidance, remembering that this outlook excludes IEEPA tariff refunds. Analyst inference
3. Track whether Medline delivers organic sales growth within its raised 10.0%-10.5% 2026 outlook; the article gives the target, not future results. Analyst inference

Evidence

• globenewswire.com